Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
Clinical trial NCT04362072 · COMPLETED
Trial details
- NCT number
- NCT04362072
- Sponsor
- Pfizer
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-29
- Primary completion
- 2024-05-29
- Enrollment
- 71
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.